 It has been a rough start for antibody discovery biotech OmniAb US:OABI since listing via a SPAC merger with Avista Public Acquisition Corp US:AHPAU cnx.cmd.pushfunction var videoId decodeURIComponent; cnx playerId: 0a52d238-33b5-4c04-ba5e-323e192cfbe8, mediaId: videoId.renderb8b49474e42e4a61905a1353db504ac9; ; in late October. 